Skip to main content

Table 2 Treatment-emergent adverse events (TEAEs) occurring in ≥20% of patients

From: A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer

  All patients (n = 40)
All Grades Grade 3 Grade 4
Hematologic TEAEs
 Neutropenia 40 (100) 19 (47.5) 2 (5.0)
 Leukopenia 40 (100) 13 (32.5) 1 (2.5)
 Anemia 13 (32.5) 0 0
 Thrombocytopenia 11 (27.5) 1 (2.5) 1 (2.5)
Non-hematologic TEAEs
 Aspartate aminotransferase increased 16 (40.0) 0 0
 Fatigue 15 (37.5) 0 0
 Blood creatinine increased 14 (35.0) 0 0
 Alanine aminotransferase increased 13 (32.5) 0 0
 Headache 13 (32.5) 0 0
 Alopecia 11 (27.5) 0 0
 Bilirubin conjugated increased 10 (25.0) 0 0
 Decreased appetite 9 (22.5) 0 0
 Constipation 8 (20.0) 0 0
 Dyspnoea 8 (20.0) 0 0
  1. Data are n (%). No grade 5 adverse events occurred